284
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience

, ORCID Icon, ORCID Icon, , , , , , , ORCID Icon, , & show all
Pages 3014-3017 | Received 01 Jun 2020, Accepted 04 Jul 2020, Published online: 28 Jul 2020

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.